The high prevalence of sexual dysfunction and inactivity in CKD treated with HD, alongside the additional evidence of HPO impairment, highlights a critical need for further study to aid in understanding the clinical effects of HPO axis disruption in CKD, alongside safe and effective treatment strategies for hormonal abnormalities and menopause in females living with CKD. The gene discussed is GFER; the disease is sexual dysfunction.